A two-center pilot study on the effects of clinical ethics support on coercive measures in psychiatryBMC PSYCHIATRYIF3.62022-06-015OAAI
A comprehensive analysis of attempted and fatal suicide cases involving frequently used psychotropic medications涉及经常使用的精神药物的未遂和致命自杀案件的综合分析GENERAL HOSPITAL PSYCHIATRYIF3.72020-03-0132PREAI
Assisted Suicide in Switzerland An Analysis of Death Records From Swiss Institutes of Forensic MedicineDEUTSCHES ARZTEBLATT INTERNATIONALIF7.12019-08-1929OA
Attitudinal variance among patients, next of kin and health care professionals towards the use of containment measures in three psychiatric hospitals in SwitzerlandBMC PSYCHIATRYIF3.62019-04-2911OAAI
Comparing Attitudes to Containment Measures of Patients, Health Care Professionals and Next of KinFRONTIERS IN PSYCHIATRYIF3.22018-10-2613OAAI
Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical TrialsANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52018-10-0152OAAI
Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 InfectionVIRUSES-BASELIF3.52018-08-283OAAI
Reasons for living and dying in suicide attempters: a two-year prospective studyBMC PSYCHIATRYIF3.62018-07-2034OAAI
Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530)JOURNAL OF MEDICINAL CHEMISTRYIF6.82018-04-1345PREAI
HCV genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with Glecaprevir and PibrentasvirJOURNAL OF HEPATOLOGYIF332018-04-010PREAI
Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in JapanANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52018-02-0135OAAI
In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor GlecaprevirANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52018-01-0169OAAI
Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavirJOURNAL OF MEDICAL VIROLOGYIF4.62017-09-2211OAAI
Acute and chronic alcohol use correlated with methods of suicide in a Swiss national sampleDRUG AND ALCOHOL DEPENDENCEIF3.62017-09-018PREAI
In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor PibrentasvirANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52017-05-01128OAAI
Resistance selection using glecaprevir and pibrentasvir in replicons of major hepatitis C virus genotypesJOURNAL OF HEPATOLOGYIF332017-01-015PREAI
Pooled resistance analysis in HCV genotype 1-6-infected patients treated with glecaprevir/pibrentasvir in phase 2 and 3 clinical trialsJOURNAL OF HEPATOLOGYIF332017-01-0124PREAI
Resistance analysis in the MAGELLAN-1 Study (Part 2): glecaprevir/pibrentasvir therapy in HCV-infected patients who had failed prior DAA regimens containing NS3/4A protease and/or NS5A inhibitorsJOURNAL OF HEPATOLOGYIF332017-01-018PREAI
Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and OmbitasvirANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52016-02-0136OAAI